Henan Lingrui Pharmaceutical Co Ltd Capital Reinvestment Ratio
Henan Lingrui Pharmaceutical Co Ltd capital reinvestment ratio. Henan Lingrui Pharmaceutical Co Ltd (600285) has a Capital Reinvestment Ratio of 0.04x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥140.12 Million) in capital expenditures (CN¥5.61 Million). Check Henan Lingrui Pharmaceutical Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
Capital reinvestment ratio of Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2025. This chart tracks Henan Lingrui Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. Also explore Henan Lingrui Pharmaceutical Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Henan Lingrui Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (1999–2025)
Henan Lingrui Pharmaceutical Co Ltd capital reinvestment ratio by year from 1999 to 2025. For the full cash flow conversion analysis, see cash efficiency ratio of Henan Lingrui Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | CN¥553.88 Million | CN¥56.83 Million | ▼ -21.9% |
| 2024 | 0.13x | CN¥875.86 Million | CN¥115.11 Million | ▲ +404.3% |
| 2023 | 0.03x | CN¥813.43 Million | CN¥21.20 Million | ▼ -19.4% |
| 2022 | 0.03x | CN¥834.91 Million | CN¥26.99 Million | ▼ -64.4% |
| 2021 | 0.09x | CN¥845.69 Million | CN¥76.91 Million | ▼ -43.0% |
| 2020 | 0.16x | CN¥450.53 Million | CN¥71.82 Million | ▲ +21.5% |
| 2019 | 0.13x | CN¥450.15 Million | CN¥59.04 Million | ▲ +9.7% |
| 2018 | 0.12x | CN¥436.25 Million | CN¥52.14 Million | ▼ -95.1% |
| 2017 | 2.43x | CN¥105.97 Million | CN¥257.55 Million | ▼ -29.5% |
| 2016 | 3.45x | CN¥63.26 Million | CN¥218.05 Million | ▲ +541.7% |
| 2015 | 0.54x | CN¥156.82 Million | CN¥84.23 Million | ▼ -34.6% |
| 2014 | 0.82x | CN¥124.32 Million | CN¥102.10 Million | ▼ -37.4% |
| 2013 | 1.31x | CN¥127.27 Million | CN¥166.88 Million | ▼ -79.9% |
| 2012 | 6.51x | CN¥15.43 Million | CN¥100.53 Million | ▲ +312.7% |
| 2011 | 1.58x | CN¥40.49 Million | CN¥63.90 Million | ▲ +364.2% |
| 2009 | 0.34x | CN¥132.61 Million | CN¥45.08 Million | ▼ -55.8% |
| 2008 | 0.77x | CN¥43.72 Million | CN¥33.63 Million | ▼ -72.6% |
| 2007 | 2.81x | CN¥15.99 Million | CN¥44.84 Million | ▲ +353.4% |
| 2006 | 0.62x | CN¥26.76 Million | CN¥16.56 Million | ▲ +8.0% |
| 2005 | 0.57x | CN¥33.43 Million | CN¥19.15 Million | ▼ -50.0% |
| 2004 | 1.14x | CN¥35.51 Million | CN¥40.65 Million | ▼ -33.3% |
| 2003 | 1.72x | CN¥23.79 Million | CN¥40.81 Million | ▲ +120.3% |
| 2002 | 0.78x | CN¥69.41 Million | CN¥54.06 Million | ▼ -92.9% |
| 2001 | 10.93x | CN¥3.41 Million | CN¥37.29 Million | ▲ +6.1% |
| 2000 | 10.31x | CN¥3.66 Million | CN¥37.76 Million | ▲ +778.6% |
| 1999 | 1.17x | CN¥4.81 Million | CN¥5.64 Million | — |